GM-CSF quantity has a selective effect on granulocytic vs. monocytic myeloid development and function
Journal Title
Frontiers in Immunology
Publication Type
Journal Article
Abstract
GM-CSF promotes myeloid differentiation of cultured bone marrow cells into cells of the granulocytic and monocytic lineage; the latter can further differentiate into monocytes/macrophages and dendritic cells. How GM-CSF selects for these different myeloid fates is unresolved. GM-CSF levels can change either iatrogenically (e.g., augmenting leukopoiesis after radiotherapy) or naturally (e.g., during infection or inflammation) resulting in different immunological outcomes. Therefore, we asked whether the dose of GM-CSF may regulate the development of three types of myeloid cells. Here, we showed that GM-CSF acted as a molecular rheostat where the quantity determined which cell type was favored; moreover, the cellular process by which this was achieved was different for each cell type. Thus, low quantities of GM-CSF promoted the granulocytic lineage, mainly through survival. High quantities promoted the monocytic lineage, mainly through proliferation, whereas moderate quantities promoted moDCs, mainly through differentiation. Finally, we demonstrated that monocytes/macrophages generated with different doses of GM-CSF differed in function. We contend that this selective effect of GM-CSF dose on myeloid differentiation and function should be taken into consideration during pathophysiological states that may alter GM-CSF levels and during GM-CSF agonistic or antagonistic therapy.
Publisher
Frontiers Media
WEHI Research Division(s)
Molecular Immunology; Immunology; Molecular Genetics Of Cancer
PubMed ID
30210491
Open Access at Publisher's Site
https://doi.org/10.3389/fimmu.2018.01922
Rights Notice
Refer to copyright notice on published article.


Creation Date: 2018-09-21 02:32:26
Last Modified: 2018-09-21 02:54:08
An error has occurred. This application may no longer respond until reloaded. Reload 🗙